15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | $1.1B | $190M | 54.7% | 28.4% | $246M | $994M | $64M |
| 2025 | $1.1B | $215M | 55.8% | 29.6% | $243M | $992M | $98M |
| 2024 | $1.1B | $209M | 55.5% | 30.4% | $239M | $1.1B | $46M |
| 2023 | $1.1B | -$82M | 55.4% | -2.0% | $222M | $1.3B | $58M |
| 2022 | $1.1B | $205M | 57.1% | 30.4% | $250M | $1.5B | $27M |
| 2021 | $943M | $165M | 58.0% | 31.5% | $213M | $1.5B | $32M |
| 2020 | $963M | $142M | 57.3% | 30.2% | $203M | $1.7B | $95M |
| 2019 | $976M | -$36M | 56.9% | 6.9% | $179M | $1.8B | $28M |
| 2018 | $1.0B | $340M | 55.4% | 20.7% | $198M | $2.0B | $33M |
| 2017 | $882M | $69M | 56.7% | 23.3% | $146M | $2.2B | $42M |
| 2016 | — | $100M | — | — | $173M | $1.6B | $27M |
| 2015 | — | $78M | — | — | $150M | $1.6B | $21M |
| 2014 | — | $73M | — | — | $109M | $934M | $28M |
| 2013 | — | $66M | — | — | $127M | $971M | $16M |
| 2012 | — | $37M | — | — | $67M | $1.1B | $19M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $282M | $54M | 51.9% | 26.8% | $38M | $994M | $64M |
| Dec '25 | $283M | $47M | 55.5% | 29.1% | $75M | $1.0B | $62M |
| Sep '25 | $274M | $42M | 55.3% | 29.1% | $55M | $993M | $119M |
| Jun '25 | $250M | $47M | 56.2% | 28.8% | $78M | $993M | $140M |
| Mar '25 | $297M | $50M | 57.3% | 29.8% | $58M | $992M | $98M |
| Dec '24 | $290M | $61M | 55.5% | 31.7% | $64M | $992M | $51M |
| Sep '24 | $284M | $54M | 55.5% | 29.7% | $68M | $1.1B | $52M |
| Jun '24 | $267M | $49M | 54.7% | 27.0% | $54M | $1.1B | $34M |
| Mar '24 | $277M | $49M | 54.8% | 29.7% | $64M | $1.1B | $46M |
| Dec '23 | $283M | $53M | 55.9% | 30.7% | $69M | $1.2B | $64M |
| Sep '23 | $286M | $54M | 55.9% | 30.8% | $60M | $1.3B | $60M |
| Jun '23 | $279M | $53M | 55.4% | 30.5% | $47M | $1.3B | $55M |
| Mar '23 | $286M | -$241M | 53.8% | -98.3% | $56M | $1.3B | $58M |
| Dec '22 | $276M | $52M | 54.6% | 31.6% | $53M | $1.4B | $86M |
| Sep '22 | $289M | $51M | 55.7% | 29.2% | $55M | $1.4B | $42M |
| Jun '22 | $277M | $55M | 57.8% | 31.4% | $57M | $1.5B | $36M |
| Mar '22 | $267M | $52M | 55.8% | 29.0% | $60M | $1.5B | $27M |
| Dec '21 | $274M | $50M | 56.5% | 30.1% | $64M | $1.5B | $21M |
| Sep '21 | $276M | $45M | 57.1% | 28.4% | $58M | $1.6B | $43M |
| Jun '21 | $269M | $58M | 59.1% | 33.9% | $68M | $1.5B | $164M |
How the market has priced PBH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Prestige Consumer Healthcare Inc.'s revenue has grown 2.9% per year, and net income grown 2.9% per year. These are computed facts, not advice.
As of FY2026, Prestige Consumer Healthcare Inc. reported $994M of total debt against $64M of cash.
In FY2026, gross margin was 54.7%, operating margin 28.4%, and net margin 17.5%.
As of Jun '26, Prestige Consumer Healthcare Inc. traded at a price-to-earnings ratio of about 11.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.